PEB: Positive Results in Kaiser Permanente User Programme, page-21

Monitor will probably have the biggest usage numbers if it can become a part of clinical guidelines. It would be aimed at patients who have had clear cystoscopies after a bladder cancer operation. Monitoring for recurrance continues in most cases for a good five years afterwards using cystoscopy at regular intervals with the existing guidelines.
A recurrance resets the cycle so in some cases patients need lifelong monitoring.

So Mal, best not to count your guinea fowl before they hatch, there is a lot to be done to change clinical procedure but this type of clinical validation of efficiency will certainly help the uptake of these tests.

PEB produced an investor update on April 6th last year so with any luck we may have a bit more to mull over this week.